Table 4.

Abstracts of Hsp90 Clinical Trials, 2004 - 2009

Inhibitor	Combined drug(s)	N1	Phase	Route	Indication	Refs
Tanespimycin	-	14	II	i.v.	Metastatic melanoma	[57]
Tanespimycin	Bortezomib	49	*	i.v.	MM	[58]
Tanespimycin	Bortezomib	72	I/II	i.v.	Relapsed and refractory MM	[31]
Tanespimycin	Trastuzumab	29	II	i.v.	HER2-positive metastatic breast cancer	[30]
17-AAG	-	17	I	i.v.	Relapsed/refractory pediatric patients with solid tumors	[59]
17-AAG	-	12	I	i.v.	Children with solid tumors	[60]
17-AAG	-	13	I	i.v.	Relapsed refractory MM	[61]
17-AAG	-	12	I	i.v.	Advanced cancer	[62]
17-AAG	-	45	I	i.v.	Advanced tumors	[63]
17-AAG	Sorafenib	16	I	i.v.	Pretreated advanced malignancy	[64]
17-AAG	Irinotecan	22	I	i.v.	Solid tumors	[65]
17-AAG	Bortezomib	20	I	i.v.	Relapsed refractory MM	[66]
17-AAG	Trastuzumab	25	I	i.v.	Advanced solid tumors	[67]
17-AAG	Docetaxel	40	I	i.v.	Solid tumors	[68]
17-AAG	Docetaxel	16	I	i.v.	Advanced solid tumors	[69]
17-AAG	Gemcitabine, Cisplatin	12	I	i.v.	Solid tumors	[70]
CNF1010	-	30	I	i.v.	Advanced solid tumors	[71]
IPI-504	-	60	I	i.v.	Advanced cancer	[72]
IPI-504	-	54	I	i.v.	Metastatic, TKI-resistant GIST or advanced/metastatic solid tumors	[36]
IPI-504	-	21	I	i.v.	Metastatic TKI-resistant GIST	[44]
IPI-504	-	19	II	i.v.	Relapsed and/or refractory stage IIIb or stage IV NSCLC	[33]
IPI-504	-	19	II	i.v.	Castration-resistant prostate cancer	[34]
IPI-504	-	12	I/II	i.v.	Relapsed and/or refractory stage IIIb or stage IV NSCLC	[73]
IPI-504	Docetaxel	16	lb	i.v.	Advanced solid tumors	[32]
Alvespimycin	-	25	I	i.v.	Advanced solid tumors	[74]
Alvespimycin	-	47	*	oral	Solid tumors	[75]
Alvespimycin	-	10	I	i.v.	Advanced, solid tumours	[76]
Alvespimycin	-	28	I	oral	Advanced malignancies	[77]
Alvespimycin	-	23	I	i.v.	Solid tumors	[78]
Alvespimycin	-	13	I	i.v.	Refractory hematological malignancies	[79]
Alvespimycin	-	37	I	i.v.	Advanced solid tumors	[80]
Alvespimycin	Trastuzumab	21	I	i.v.	H-refractory HER2+ metastatic breast cancer and refractory ovarian cancer	[81]
BIIB021	-	23	I	oral	Advanced solid tumors or CLL	[82]
SNX-5422	-	11	I	oral	Refractory solid tumors or lymphomas	[83]
KW-2478	-	15	I	i.v.	Refractory MM, CLL, NHL	[84]
AUY922	-	44	I	i.v.	Advanced solid malignancies	[85]
AUY922	-	40	I	i.v.	Solid tumors	[86]

¹number of patients;

^*not specified